CSL (OTCMKTS:CSLLY) Hits New 1-Year Low – Should You Sell?

CSL Limited Sponsored ADR (OTCMKTS:CSLLY)’s share price hit a new 52-week low on Tuesday . The stock traded as low as $16.01 and last traded at $17.26, with a volume of 334195 shares. The stock had previously closed at $17.08.

Wall Street Analyst Weigh In

CSLLY has been the topic of several recent research reports. Zacks Research cut CSL from a “hold” rating to a “strong sell” rating in a report on Monday, May 11th. Jefferies Financial Group lowered shares of CSL from a “strong-buy” rating to a “hold” rating in a research report on Friday, May 29th. Royal Bank Of Canada lowered shares of CSL from a “moderate buy” rating to a “hold” rating in a research report on Wednesday, February 11th. Citigroup lowered shares of CSL from a “strong-buy” rating to a “hold” rating in a research report on Monday, May 11th. Finally, Canaccord Genuity Group lowered shares of CSL from a “strong-buy” rating to a “hold” rating in a research report on Monday, May 11th. Four research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, CSL has an average rating of “Reduce”.

CSL Stock Performance

The company has a current ratio of 2.57, a quick ratio of 1.15 and a debt-to-equity ratio of 0.51. The company’s 50-day moving average price is $20.88 and its 200 day moving average price is $40.39.

About CSL

CSL Limited (OTCMKTS: CSLLY) is a global biotechnology company headquartered in Melbourne, Australia that develops, manufactures and delivers a range of plasma-derived and recombinant therapeutics, vaccines and related services. Its principal businesses include CSL Behring, which focuses on specialty biotherapies for bleeding disorders, immune deficiencies, hereditary angioedema and other serious conditions; Seqirus, an influenza vaccine company formed following CSL’s acquisition of Novartis’ influenza vaccine business; and CSL Plasma, a network of plasma collection centers that supplies the raw material for many of its therapies.

The company’s product portfolio spans immunoglobulins, clotting factor concentrates, albumin and other protein-based treatments used in the management of chronic and acute rare diseases, as well as seasonal and pandemic influenza vaccines.